Literature DB >> 20347868

The role of serum cryptococcal antigen screening for the early diagnosis of cryptococcosis in HIV-infected patients with different ranges of CD4 cell counts.

Pannee Pongsai1, Kalayanee Atamasirikul, Somnuek Sungkanuparph.   

Abstract

OBJECTIVE: To determine the role of serum cryptococcal antigen (SCA) for the screening of cryptococcosis in HIV-infected patients with different ranges of CD4 cell counts.
METHODS: A retrospective cohort study was conducted in antiretroviral-naïve HIV-infected patients who had no symptom and had been screened with SCA in a tertiary-care hospital. Prevalence of positive SCA at different ranges of CD4 cell counts, risk factor of positive SCA, and incidence of cryptococcosis during one-year follow-up period after negative SCA were determined.
RESULTS: There were 131 patients with a mean age of 38.5 years; 61.8% were male. Median (range) CD4 was 62 (3-590) cells/mm(3). The overall prevalence of positive SCA was 9.2%. This prevalence in patients with CD4 < 100, 100-199, and >or=200 cells/mm(3) were 12.9%, 3.6%, and 0%, respectively (P = 0.041). In multivariate analysis, CD4 < 100 cells/mm(3) was associated with positive SCA (OR = 6.69; 95% CI, 1.03-23.56). Four (33.3%) of 12 patients with positive SCA had cryptococcosis whereas one (0.8%) of 119 patients with negative SCA developed meningitis at one-year follow-up.
CONCLUSIONS: SCA screening has a substantial role for the early detection of cryptococcal infection in HIV-infected patients with low CD4 cell counts. Routine screening with SCA should be performed in patients with CD4 < 100 cells/mm(3). Copyright (c) 2010 The British Infection Society. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20347868     DOI: 10.1016/j.jinf.2010.03.015

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


  42 in total

1.  Screening for cryptococcal antigenemia in anti-retroviral naïve AIDS patients in benin city, Nigeria.

Authors:  Favour Osazuwa; John Osilume Dirisu; Patrick Evbaguehita Okuonghae; Ose Ugbebor
Journal:  Oman Med J       Date:  2012-05

2.  Cost-effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4+ cell count < or = 100 cells/microL who start HIV therapy in resource-limited settings.

Authors:  David B Meya; Yukari C Manabe; Barbara Castelnuovo; Bethany A Cook; Ali M Elbireer; Andrew Kambugu; Moses R Kamya; Paul R Bohjanen; David R Boulware
Journal:  Clin Infect Dis       Date:  2010-08-15       Impact factor: 9.079

3.  Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis.

Authors:  Radha Rajasingham; Rachel M Smith; Benjamin J Park; Joseph N Jarvis; Nelesh P Govender; Tom M Chiller; David W Denning; Angela Loyse; David R Boulware
Journal:  Lancet Infect Dis       Date:  2017-05-05       Impact factor: 25.071

4.  Prevalence, correlates, and outcomes of cryptococcal antigen positivity among patients with AIDS, United States, 1986-2012.

Authors:  Jennie McKenney; Sean Bauman; Brandon Neary; Roger Detels; Audrey French; Joseph Margolick; Brian Doherty; Jeffrey D Klausner
Journal:  Clin Infect Dis       Date:  2014-11-24       Impact factor: 9.079

Review 5.  Integrating cryptococcal antigen screening and pre-emptive treatment into routine HIV care.

Authors:  Radha Rajasingham; David B Meya; David R Boulware
Journal:  J Acquir Immune Defic Syndr       Date:  2012-04-15       Impact factor: 3.731

Review 6.  New insights in the prevention, diagnosis, and treatment of cryptococcal meningitis.

Authors:  Arthur Jackson; Charles van der Horst
Journal:  Curr HIV/AIDS Rep       Date:  2012-09       Impact factor: 5.071

7.  Cost-effectiveness of primary prophylaxis of AIDS associated cryptococcosis in Cambodia.

Authors:  Romain Micol; Ayden Tajahmady; Olivier Lortholary; Suna Balkan; Catherine Quillet; Jean-Philippe Dousset; Hak Chanroeun; Yoann Madec; Arnaud Fontanet; Yazdan Yazdanpanah
Journal:  PLoS One       Date:  2010-11-09       Impact factor: 3.240

Review 8.  Asymptomatic cryptococcemia in resource-limited settings.

Authors:  Ana-Claire Meyer; Mark Jacobson
Journal:  Curr HIV/AIDS Rep       Date:  2013-09       Impact factor: 5.071

9.  The impact of routine cryptococcal antigen screening on survival among HIV-infected individuals with advanced immunosuppression in Kenya.

Authors:  A-C L Meyer; C K Kendi; J A Penner; N Odhiambo; B Otieno; E Omondi; E Opiyo; E A Bukusi; C R Cohen
Journal:  Trop Med Int Health       Date:  2013-02-01       Impact factor: 2.622

10.  High Cryptococcal Antigen Titers in Blood Are Predictive of Subclinical Cryptococcal Meningitis Among Human Immunodeficiency Virus-Infected Patients.

Authors:  Rachel M Wake; Erika Britz; Charlotte Sriruttan; Ivy Rukasha; Tanvier Omar; David C Spencer; Jeremy S Nel; Sello Mashamaite; Adeboye Adelekan; Tom M Chiller; Joseph N Jarvis; Thomas S Harrison; Nelesh P Govender
Journal:  Clin Infect Dis       Date:  2018-02-10       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.